HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Equity Capital Markets

Annoroad Gene Technology / Equity Capital Markets

<ul>
<li>Annoroad has its competitiveness in the industry, but in a complex market environment, the comprehensive product lines may not necessarily bring high performance growth and large revenue scale.</li>
<li>The prenatal testing business is not easy. VBP is headwind.After Illumina was listed on "Unreliable Entity List", it’s uncertain whether NextSeq 550AR sequencer can continue to be sold in China.</li>
<li>Taking into account the future growth uncertainty/centralized procurement/competitive pressure/lack of deep layout of the entire industry chain/policy risks, it's already good to have a valuation of RMB2-3.5 billion after IPO</li>
</ul>


Annoroad has its competitiveness in the industry, but in a complex market environment, the comprehensive product lines may not necessarily bring high performance growth and large revenue scale.
The prenatal testing business is not easy. VBP is headwind.After Illumina was listed on "Unreliable Entity List", it’s uncertain whether NextSeq 550AR sequencer can continue to be sold in China.
Taking into account the future growth uncertainty/centralized procurement/competitive pressure/lack of deep layout of the entire industry chain/policy risks, it's already good to have a valuation of RMB2-3.5 billion after IPO


Pre-IPO Annoroad Gene Technology - The Outlook Is Not Optimistic

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Annoroad Gene Technology (AGT HK)

Pre-IPO Annoroad Gene Technology - The Outlook Is Not Optimistic

Due to the future growth uncertainty/centralized procurement/competitive pressure/lack of deep layout of the entire industry chain/policy risks,...

Xinyao (Criss) Wang

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)